Phil King discusses the Opthea fiasco, his current outlook and whether we’ve seen the bottom in equity markets.

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on 908 Devices (MASS – Research Report), LENZ ...

In a report released on April 11, Elyse Shapiro from Canaccord Genuity maintained a Hold rating on Mayne Pharma Group (MAYNF – Research ...

Australian-US biotech Opthea Ltd has reported disappointing phase 3 results with its lead drug for vision-robbing disease wet age-related macular degeneration (AMD), throwing its future into doubt.

EBR Systems, backed by investors such as HESTA, Hostplus and private equity veteran Mark Carnegie, can start selling its technology within months.

Story April 10 - Opthea: Days after back-to-back flops sank an eye disease asset, the biotech revealed plans to lay off 65% of its staff and operate with a skeleton crew to save money. Story April ...

Argenx's Vyvgart Hytrulo gets FDA approval for self-injection syringe, Opthea cuts 65% staff after trial failures, ...

Shares drop 1.8pc at the closing bell after US imposes 104pc China tariff; Treasuries sell-off; RBNZ cuts rates by 25bps; oil, iron ore sink; Regal’s $540m Opthea blow. Sharemarket rebounds as ...

Real time quote data is not available at this time. *Data is provided by Barchart.com. Data reflects weightings calculated at the beginning of each month. Data is subject to change. **Green ...

The pair examine industry trends, company closures, developments in the cell and gene space—and the reductions in force ...

Positive early stage data for Verve Therapeutics Inc.’s base editing therapy points to a range of development options, including bringing partner Eli Lilly and Co. in a little closer. Verve’s Heart-2 ...